drugset / Trial / NCT00955357

Trial to Assess Lacosamide as the First add-on Anti-epileptic Drug Treatment in Patients With Partial-onset Seizures

NCT00955357

Phase 4 Completed 461 enrolled UCB Pharma
Non-randomizedParallel-groupOpen-labelTreatment

Summary

To evaluate the efficacy and safety of oral Lacosamide as first add on treatment in subjects with uncontrolled partial-onset seizures after prior treatment with a monotherapy Antiepileptic Drug (AED) regimen compared to subjects who have received treatment with at least 2 AEDs.

Timeline

Start
2009-08
Primary completion
2013-04
Completion
2013-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Lacosamide Other / unclassified 150 mg Oral
Subject Lacosamide Other / unclassified 200 mg Oral

Indications